Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis

Carla Casulo, Jonathan W. Friedberg, Kwang W. Ahn, Christopher Flowers, Alyssa DiGilio, Sonali M. Smith, Sairah Ahmed, David Inwards, Mahmoud Aljurf, Andy I. Chen, Hannah Choe, Jonathon Cohen, Edward Copelan, Umar Farooq, Timothy S. Fenske, Cesar Freytes, Sameh Gaballa, Siddhartha Ganguly, Yogesh Jethava, Rammurti T. Kamble & 16 others Vaishalee P. Kenkre, Hillard Lazarus, Aleksandr Lazaryan, Richard F. Olsson, Andrew R. Rezvani, David Rizzieri, Sachiko Seo, Gunjan L. Shah, Nina Shah, Melham Solh, Anna Sureda, Basem William, Aaron Cumpston, Andrew D. Zelenetz, Brian K. Link, Mehdi Hamadani

Research output: Contribution to journalArticle

Abstract

Patients with follicular lymphoma (FL) experiencing early therapy failure (ETF) within 2 years of frontline chemoimmunotherapy have poor overall survival (OS). We analyzed data from the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National LymphoCare Study (NLCS) to determine whether autologous hematopoietic cell transplant (autoHCT) can improve outcomes in this high-risk FL subgroup. ETF was defined as failure to achieve at least partial response after frontline chemoimmunotherapy or lymphoma progression within 2 years of frontline chemoimmunotherapy. We identified 2 groups: the non-autoHCT cohort (patients from the NLCS with ETF not undergoing autoHCT) and the autoHCT cohort (CIBMTR patients with ETF undergoing autoHCT). All patients received rituximab-based chemotherapy as frontline treatment; 174 non-autoHCT patients and 175 autoHCT patients were identified and analyzed. There was no difference in 5-year OS between the 2 groups (60% versus 67%, respectively; P = .16). A planned subgroup analysis showed that patients with ETF receiving autoHCT soon after treatment failure (≤1 year of ETF; n = 123) had higher 5-year OS than those without autoHCT (73% versus 60%, P = .05). On multivariate analysis, early use of autoHCT was associated with significantly reduced mortality (hazard ratio, .63; 95% confidence interval, .42 to .94; P = .02). Patients with FL experiencing ETF after frontline chemoimmunotherapy lack optimal therapy. We demonstrate improved OS when receiving autoHCT within 1 year of treatment failure. Results from this unique collaboration between the NLCS and CIBMTR support consideration of early consolidation with autoHCT in select FL patients experiencing ETF.

LanguageEnglish (US)
JournalBiology of Blood and Marrow Transplantation
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Follicular Lymphoma
Autologous Transplantation
Secondary Prevention
Bone Marrow
Transplants
Research
Survival
Rituximab
Treatment Failure

Keywords

  • Autologous transplantation
  • Chemoimmunotherapy
  • Early therapy failure
  • Early transplant
  • Follicular lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure : A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. / Casulo, Carla; Friedberg, Jonathan W.; Ahn, Kwang W.; Flowers, Christopher; DiGilio, Alyssa; Smith, Sonali M.; Ahmed, Sairah; Inwards, David; Aljurf, Mahmoud; Chen, Andy I.; Choe, Hannah; Cohen, Jonathon; Copelan, Edward; Farooq, Umar; Fenske, Timothy S.; Freytes, Cesar; Gaballa, Sameh; Ganguly, Siddhartha; Jethava, Yogesh; Kamble, Rammurti T.; Kenkre, Vaishalee P.; Lazarus, Hillard; Lazaryan, Aleksandr; Olsson, Richard F.; Rezvani, Andrew R.; Rizzieri, David; Seo, Sachiko; Shah, Gunjan L.; Shah, Nina; Solh, Melham; Sureda, Anna; William, Basem; Cumpston, Aaron; Zelenetz, Andrew D.; Link, Brian K.; Hamadani, Mehdi.

In: Biology of Blood and Marrow Transplantation, 01.01.2018.

Research output: Contribution to journalArticle

Casulo, C, Friedberg, JW, Ahn, KW, Flowers, C, DiGilio, A, Smith, SM, Ahmed, S, Inwards, D, Aljurf, M, Chen, AI, Choe, H, Cohen, J, Copelan, E, Farooq, U, Fenske, TS, Freytes, C, Gaballa, S, Ganguly, S, Jethava, Y, Kamble, RT, Kenkre, VP, Lazarus, H, Lazaryan, A, Olsson, RF, Rezvani, AR, Rizzieri, D, Seo, S, Shah, GL, Shah, N, Solh, M, Sureda, A, William, B, Cumpston, A, Zelenetz, AD, Link, BK & Hamadani, M 2018, 'Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis' Biology of Blood and Marrow Transplantation. DOI: 10.1016/j.bbmt.2017.12.771
Casulo, Carla ; Friedberg, Jonathan W. ; Ahn, Kwang W. ; Flowers, Christopher ; DiGilio, Alyssa ; Smith, Sonali M. ; Ahmed, Sairah ; Inwards, David ; Aljurf, Mahmoud ; Chen, Andy I. ; Choe, Hannah ; Cohen, Jonathon ; Copelan, Edward ; Farooq, Umar ; Fenske, Timothy S. ; Freytes, Cesar ; Gaballa, Sameh ; Ganguly, Siddhartha ; Jethava, Yogesh ; Kamble, Rammurti T. ; Kenkre, Vaishalee P. ; Lazarus, Hillard ; Lazaryan, Aleksandr ; Olsson, Richard F. ; Rezvani, Andrew R. ; Rizzieri, David ; Seo, Sachiko ; Shah, Gunjan L. ; Shah, Nina ; Solh, Melham ; Sureda, Anna ; William, Basem ; Cumpston, Aaron ; Zelenetz, Andrew D. ; Link, Brian K. ; Hamadani, Mehdi. / Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure : A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. In: Biology of Blood and Marrow Transplantation. 2018
@article{5c8a80a73e254459b27fdc7bdd74bde8,
title = "Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis",
abstract = "Patients with follicular lymphoma (FL) experiencing early therapy failure (ETF) within 2 years of frontline chemoimmunotherapy have poor overall survival (OS). We analyzed data from the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National LymphoCare Study (NLCS) to determine whether autologous hematopoietic cell transplant (autoHCT) can improve outcomes in this high-risk FL subgroup. ETF was defined as failure to achieve at least partial response after frontline chemoimmunotherapy or lymphoma progression within 2 years of frontline chemoimmunotherapy. We identified 2 groups: the non-autoHCT cohort (patients from the NLCS with ETF not undergoing autoHCT) and the autoHCT cohort (CIBMTR patients with ETF undergoing autoHCT). All patients received rituximab-based chemotherapy as frontline treatment; 174 non-autoHCT patients and 175 autoHCT patients were identified and analyzed. There was no difference in 5-year OS between the 2 groups (60{\%} versus 67{\%}, respectively; P = .16). A planned subgroup analysis showed that patients with ETF receiving autoHCT soon after treatment failure (≤1 year of ETF; n = 123) had higher 5-year OS than those without autoHCT (73{\%} versus 60{\%}, P = .05). On multivariate analysis, early use of autoHCT was associated with significantly reduced mortality (hazard ratio, .63; 95{\%} confidence interval, .42 to .94; P = .02). Patients with FL experiencing ETF after frontline chemoimmunotherapy lack optimal therapy. We demonstrate improved OS when receiving autoHCT within 1 year of treatment failure. Results from this unique collaboration between the NLCS and CIBMTR support consideration of early consolidation with autoHCT in select FL patients experiencing ETF.",
keywords = "Autologous transplantation, Chemoimmunotherapy, Early therapy failure, Early transplant, Follicular lymphoma, Rituximab",
author = "Carla Casulo and Friedberg, {Jonathan W.} and Ahn, {Kwang W.} and Christopher Flowers and Alyssa DiGilio and Smith, {Sonali M.} and Sairah Ahmed and David Inwards and Mahmoud Aljurf and Chen, {Andy I.} and Hannah Choe and Jonathon Cohen and Edward Copelan and Umar Farooq and Fenske, {Timothy S.} and Cesar Freytes and Sameh Gaballa and Siddhartha Ganguly and Yogesh Jethava and Kamble, {Rammurti T.} and Kenkre, {Vaishalee P.} and Hillard Lazarus and Aleksandr Lazaryan and Olsson, {Richard F.} and Rezvani, {Andrew R.} and David Rizzieri and Sachiko Seo and Shah, {Gunjan L.} and Nina Shah and Melham Solh and Anna Sureda and Basem William and Aaron Cumpston and Zelenetz, {Andrew D.} and Link, {Brian K.} and Mehdi Hamadani",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2017.12.771",
language = "English (US)",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure

T2 - Biology of Blood and Marrow Transplantation

AU - Casulo,Carla

AU - Friedberg,Jonathan W.

AU - Ahn,Kwang W.

AU - Flowers,Christopher

AU - DiGilio,Alyssa

AU - Smith,Sonali M.

AU - Ahmed,Sairah

AU - Inwards,David

AU - Aljurf,Mahmoud

AU - Chen,Andy I.

AU - Choe,Hannah

AU - Cohen,Jonathon

AU - Copelan,Edward

AU - Farooq,Umar

AU - Fenske,Timothy S.

AU - Freytes,Cesar

AU - Gaballa,Sameh

AU - Ganguly,Siddhartha

AU - Jethava,Yogesh

AU - Kamble,Rammurti T.

AU - Kenkre,Vaishalee P.

AU - Lazarus,Hillard

AU - Lazaryan,Aleksandr

AU - Olsson,Richard F.

AU - Rezvani,Andrew R.

AU - Rizzieri,David

AU - Seo,Sachiko

AU - Shah,Gunjan L.

AU - Shah,Nina

AU - Solh,Melham

AU - Sureda,Anna

AU - William,Basem

AU - Cumpston,Aaron

AU - Zelenetz,Andrew D.

AU - Link,Brian K.

AU - Hamadani,Mehdi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Patients with follicular lymphoma (FL) experiencing early therapy failure (ETF) within 2 years of frontline chemoimmunotherapy have poor overall survival (OS). We analyzed data from the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National LymphoCare Study (NLCS) to determine whether autologous hematopoietic cell transplant (autoHCT) can improve outcomes in this high-risk FL subgroup. ETF was defined as failure to achieve at least partial response after frontline chemoimmunotherapy or lymphoma progression within 2 years of frontline chemoimmunotherapy. We identified 2 groups: the non-autoHCT cohort (patients from the NLCS with ETF not undergoing autoHCT) and the autoHCT cohort (CIBMTR patients with ETF undergoing autoHCT). All patients received rituximab-based chemotherapy as frontline treatment; 174 non-autoHCT patients and 175 autoHCT patients were identified and analyzed. There was no difference in 5-year OS between the 2 groups (60% versus 67%, respectively; P = .16). A planned subgroup analysis showed that patients with ETF receiving autoHCT soon after treatment failure (≤1 year of ETF; n = 123) had higher 5-year OS than those without autoHCT (73% versus 60%, P = .05). On multivariate analysis, early use of autoHCT was associated with significantly reduced mortality (hazard ratio, .63; 95% confidence interval, .42 to .94; P = .02). Patients with FL experiencing ETF after frontline chemoimmunotherapy lack optimal therapy. We demonstrate improved OS when receiving autoHCT within 1 year of treatment failure. Results from this unique collaboration between the NLCS and CIBMTR support consideration of early consolidation with autoHCT in select FL patients experiencing ETF.

AB - Patients with follicular lymphoma (FL) experiencing early therapy failure (ETF) within 2 years of frontline chemoimmunotherapy have poor overall survival (OS). We analyzed data from the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National LymphoCare Study (NLCS) to determine whether autologous hematopoietic cell transplant (autoHCT) can improve outcomes in this high-risk FL subgroup. ETF was defined as failure to achieve at least partial response after frontline chemoimmunotherapy or lymphoma progression within 2 years of frontline chemoimmunotherapy. We identified 2 groups: the non-autoHCT cohort (patients from the NLCS with ETF not undergoing autoHCT) and the autoHCT cohort (CIBMTR patients with ETF undergoing autoHCT). All patients received rituximab-based chemotherapy as frontline treatment; 174 non-autoHCT patients and 175 autoHCT patients were identified and analyzed. There was no difference in 5-year OS between the 2 groups (60% versus 67%, respectively; P = .16). A planned subgroup analysis showed that patients with ETF receiving autoHCT soon after treatment failure (≤1 year of ETF; n = 123) had higher 5-year OS than those without autoHCT (73% versus 60%, P = .05). On multivariate analysis, early use of autoHCT was associated with significantly reduced mortality (hazard ratio, .63; 95% confidence interval, .42 to .94; P = .02). Patients with FL experiencing ETF after frontline chemoimmunotherapy lack optimal therapy. We demonstrate improved OS when receiving autoHCT within 1 year of treatment failure. Results from this unique collaboration between the NLCS and CIBMTR support consideration of early consolidation with autoHCT in select FL patients experiencing ETF.

KW - Autologous transplantation

KW - Chemoimmunotherapy

KW - Early therapy failure

KW - Early transplant

KW - Follicular lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=85040541734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040541734&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2017.12.771

DO - 10.1016/j.bbmt.2017.12.771

M3 - Article

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

ER -